Search results
Results from the WOW.Com Content Network
Arsphenamine, also known as Salvarsan or compound 606, is an antibiotic drug that was introduced at the beginning of the 1910s as the first effective treatment for the deadly infectious diseases syphilis, relapsing fever, and African trypanosomiasis. [2] [3] This organoarsenic compound was the first modern antimicrobial agent. [4]
This was the first agent with a specific therapeutic effect to be created on the basis of theoretical considerations. Salvarsan proved to be amazingly effective, particularly when compared with the conventional therapy of mercury salts. Manufactured by Hoechst AG, Salvarsan became the most widely prescribed drug in the world.
1911 – Arsphenamine, also Salvarsan [1] 1912 – Neosalvarsan; 1935 – Prontosil (an oral precursor to sulfanilamide), the first sulfonamide; 1936 – Sulfanilamide; 1938 – Sulfapyridine (M&B 693) 1939 – sulfacetamide; 1940 – sulfamethizole; 1942 – benzylpenicillin, the first penicillin; 1942 – gramicidin S, the first peptide ...
In 1907 Alfred Bertheim synthesized Arsphenamine, the first man-made antibiotic. In 1927 Erik Rotheim patented the first aerosol spray can. In 1933 Robert Pauli Scherer created a method to develop softgels. William Roberts studies about penicillin were continued by Alexander Fleming, who in 1928 concluded that penicillin had an antibiotic ...
Therefore, Hata's and Ehrlich's work represents a turning point for experimental and therapeutic pharmacology and paved the way for the development of antibiotics decades later. [4] Salvarsan was established as the standard treatment for syphilis until it was replaced by the antibiotic penicillin after World War II, which has fewer adverse side ...
Salvarsan was commercially introduced in 1910, and in 1913, a less toxic form, "Neosalvarsan" (Compound 914), was released in the market. These drugs became the principal treatments of syphilis until the arrival of penicillin and other novel antibiotics towards the middle of the 20th century. [7]
Both Salvarsan and Neosalvarsan were developed in the laboratory of Paul Ehrlich in Frankfurt, Germany. Their discoveries were the result of the first organized team effort to optimize the biological activity of a lead compound through systematic chemical modifications. [1] This scheme is the basis for most modern pharmaceutical research.
The organoarsenic compound Salvarsan was the first synthetic chemotherapeutic agent, discovered by Paul Ehrlich. [21] The treatment, however, led to many problems causing long lasting health complications. [22] Around 1943 it was finally superseded by penicillin.